Health Care · Services-Medical Laboratories · Nasdaq · CIK 2070849 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $133.64Day +4.42%Mkt cap $2.8BP/E (FY) 380.6×Off 52W high −3.6%Vol (1Y) 87.7%
Daily closing price, split-adjusted to the current basis; 0.7y shown of 170 bars on file. Sampled to 170 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest11.3% of sh out |
| Days to cover3.6d |
| 13F net flow (QoQ)+6.65% |
| Top-10 13F concentration69.1% |
| Next report (est.)2026-10-01 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)380.6× |
| Sales (TTM)$305.1M |
| Earnings (TTM)$7.5M |
| Net margin2.4% |
| Debt / equity0.12× |
| Total debt / EBITDA2.50× |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+63.3% |
Total return through 2026-07-28 · series begins 2025-11-06. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)87.7% |
| Ann. volatility (3Y)87.7% |
| Sharpe (1Y)0.78 |
| Sharpe (3Y)0.78 |
| Max drawdown (1Y)−50.8% |
| Max drawdown (3Y)−50.8% |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| ADAMS STREET PARTNERS LLC | 1.7M | $135M | 8.06% | +0.0% |
| BAILLIE GIFFORD & CO | 1.3M | $99M | 5.93% | −0.6% |
| Civilization Ventures Management, LLC | 1.1M | $87M | 5.18% | +0.0% |
| BAMCO INC /NY/ | 741,485 | $59M | 3.49% | +336.2% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 737,518 | $58M | 3.47% | +52.0% |
| NVP ASSOCIATES, LLC | 513,330 | $41M | 2.42% | +0.0% |
| NEUBERGER BERMAN GROUP LLC | 709,214 | $38M | 3.34% | +1.2% |
| Invesco Ltd. | 406,512 | $32M | 1.91% | +114.2% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | $0.34 | — | $108.4M | +83.8% |
| 2025-09-30 | 2025-12-09 | $0.10 | — | $83.5M | +117.4% |
| 2025-03-31 | — | −$0.39 | — | $59.0M | — |
| 2024-09-30 | — | −$1.47 | — | $38.4M | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-01 is ESTIMATED from filing cadence (median gap 74d) — not company-confirmed.
Prenatal 91% · Oncology 8% · Clinical Trial Support And Other Services 1%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
